Patient adherence to allergy immunotherapy

Current Opinion in Otolaryngology and Head and Neck Surgery

Volumn 21, Issue 3, 2013, Pages 256-262

  Reisacher, William R ^a   Visaya, Jiovani M ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b NONE

Author keywords

adherence; allergic rhinitis; SCIT; SLIT

Indexed keywords

ANTIALLERGIC AGENT;

AGE; ALLERGIC ASTHMA; ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ALLERGIC RHINITIS; CHRONIC ASPECIFIC RESPIRATORY TRACT DISEASE; DRUG EFFICACY; DRUG SAFETY; EDUCATIONAL STATUS; ETHNIC DIFFERENCE; FOLLOW UP; HAY FEVER; HEALTH BELIEF MODEL; HUMAN; IMMUNOTHERAPY; INTERPERSONAL COMMUNICATION; NEURODERMATITIS; PATIENT COMPLIANCE; PATIENT MONITORING; POLLEN ALLERGY; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RELIGION; RESPIRATORY TRACT ALLERGY; REVIEW; RHINITIS; RHINOCONJUNCTIVITIS; SELF CONCEPT; SEX DIFFERENCE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; PATIENT COMPLIANCE;

EID: 84877724944     PISSN: 10689508     EISSN: 15316998     Source Type: Journal    
DOI: 10.1097/MOO.0b013e32835f8048     Document Type: Review

References (50)

1. Koberlein J, Kothe AC, Schaffert C. Determinants of patient compliance in allergic rhinoconjunctivitis. Curr Opin Allergy Clin Immunol 2011; 11:192-199.
2. Horwitz RI, Horwitz SM. Adherence to treatment and health outcomes. Arch Intern Med 1993; 153:1863-1868.
3. Bell JS, Airaksinen MS, Lyles A, et al. Concordance is not synonymous with compliance or adherence. Br J Clin Pharmacol 2007; 64:710-711.
4. Mardby AC, Akerlind I, Jorgensen T. Beliefs about medicines and self-reported adherence among pharmacy clients. Patient Educ Couns 2007; 69:158-164.
5. Horne R, Weinman J, Barber N, et al. Concordance, adherence and compliance in medicine taking: report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). 2005.
6. Bourdin A, Halimi L, Vachier I, et al. Adherence in severe asthma. Clin Exp Allergy 2012; 42:1566-1574.
7. Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007; CD001936.
8. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjuncti- vitis. J Allergy Clin Immunol 2004; 114:851-857.
9. Sencan NM, Wertheimer A, Levine CB. What determines the duration of patient medication compliance in patients with chronic disease: are we looking in the wrong place? South Med Rev 2011; 4:97-101.
10. Homedes N, Ugalde A. Patients' compliance with medical treatments in the third world. What do we know? Health Policy Plan 1993; 8:291-314.
11. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004; 42:200-209.
12. Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract 1990; 40:114-116.
13. Vermeire E, Hearnshaw H, Van Royen P, et al. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 2001; 26:331-342.
14. Demoly P, Allaert FA, Lecasble M, et al. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 2002; 57:546-554.
15. Witticke D, Seidling HM, Klimm HD, et al. Do we prescribe what patients prefer? Pilot study to assess patient preferences for medication regimen characteristics. Patient Prefer Adherence 2012; 6:679-684.
16. Bultman DC, Svarstad BL. Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. Patient Educ Couns 2000; 40:173-185.
17. Bull SA, Hu XH, Hunkeler EM, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288:1403-1409.
18. Britten N. Patients' expectations of consultations. BMJ 2004; 328:416-417.
19. Cushing A, Metcalfe R. Optimizing medicines management: from compliance to concordance. Ther Clin Risk Manag 2007; 3:1047-1058.
20. Cook CL, Wade WE, Martin BC, et al. Concordance among three self-reported measures of medication adherence and pharmacy refill records.J Am Pharm Assoc 2005; 45:151-159.
21. Sade K, Berkun Y, Dolev Z, et al. Knowledge and expectations of patients receiving aeroallergen immunotherapy. Ann Allergy Asthma Immunol 2003; 91:444-448.
22. Cohn JR, Pizzi A. Determinants of patient compliance with allergen immu-notherapy. J Allergy Clin Immunol 1993; 91:734-737.
23. Lower T, Henry J, Mandik L, et al. Compliance with allergen immunotherapy. Ann Allergy 1993; 70:480-482.
24. Tinkelman D, Smith F, Cole WQ 3rd, et al. Compliance with an allergen immunotherapy regime. Ann Allergy Asthma Immunol 1995; 74:241-246.
25. Ruiz FJ, Jimenez A, Cocoletzi J, et al. [Compliance with and abandonment of immunotherapy]. Rev Alerg Mex 1997; 44:42-44.
26. Donahue JG, Greineder DK, Connor-Lacke L, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999; 82:339-347.
27. Rhodes BJ. Patient dropouts before completion of optimal dose, multiple allergen immunotherapy. Ann Allergy Asthma Immunol 1999; 82:281-286.
28. More DR, Hagan LL. Factors affecting compliance with allergen immunother-apy at a military medical center. Ann Allergy Asthma Immunol 2002; 88:391-394.
29. Pajno GB, Vita D, Caminiti L, et al. Children's compliance with allergen immunotherapy according to administration routes. J Allergy Clin Immunol 2005; 116:1380-1381.
30. Hommers L, Ellert U, Scheidt-Nave C, et al. Factors contributing to conductance and outcome of specific immunotherapy: data from the German National Health Interview and Examination Survey. Eur J Public Health 2007; 17:278-284.
31. Hankin CS, Cox L, Lang D, et al. Allergy immunotherapy among Medicaid-enrolled children with allergic rhinitis: patterns of care, resource use, and costs. J Allergy Clin Immunol 2008; 121:227-232.
32. Mahesh PA, Vedanthan PK, Amrutha DH, et al. Factors associated with nonadherence to specific allergen immunotherapy in management of respiratory allergy. Indian J Chest Dis Allied Sci 2010; 52:91-95.
33. Hsu NM, Reisacher WR. A comparison of attrition rates in patients under-going sublingual immunotherapy vs subcutaneous immunotherapy. Int Forum Allergy Rhinol 2012; 2:280-284.
34. Kuang L, Feng H, Xie B. [Efficacy and compliance of specific immunotherapy in allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2012; 26:56-58.
35. Marogna M, Spadolini I, Massolo A, et al. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004; 59:1205-1210.
36. Lombardi C, Gani F, Landi M, et al. Quantitative assessment of the adherence to sublingual immunotherapy. J Allergy Clin Immunol 2004; 113:1219-1220.
37. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). J Allergy Clin Immunol 2006; 117:946-948.
38. Passalacqua G, Musarra A, Pecora S, et al. Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY project: evaluation of a novel SLIT formulation during a year). Pediatr Allergy Immunol 2007; 18:58-62.
39. Cadario G, Ciprandi G, Di Cara G, et al. Comparison between continuous or intermittent schedules of sublingual immunotherapy for house dust mites: effects on compliance, patients satisfaction, quality of life and safety. Int J Immunopathol Pharmacol 2008; 21:471-473.
40. Roder E, Berger MY, de Groot H, et al. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. Clin Exp Allergy 2008; 38:1659-1667.
41. Shaikh WA, Shaikh SW. Allergies in India: a study on medication compliance. J Indian Med Assoc 2009; 107:462-463.
42. Chang H, Han DH, Mo JH, et al. Early compliance and efficacy of sublingual immunotherapy in patients with allergic rhinitis for house dust mites. Clin Exp Otorhinolaryngol 2009; 2:136-140.
43. Jansen A, Andersen KF, Bruning H. Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: an a priori subgroup analysis. Clin Ther 2009; 31:321-327.
44. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immu-notherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009; 64:179-186.
45. Vita D, Caminiti L, Ruggeri P, et al. Sublingual immunotherapy: adherence based on timing and monitoring control visits. Allergy 2010; 65:668-669.
46. Migueres M, Fontaine JF, Haddad T, et al. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). Int J Immunopathol Pharmacol 2011; 24:387-400.
47. Pajno GB, Caminiti L, Crisafulli G, et al. Adherence to sublingual immunother-apy in preschool children. Pediatr Allergy Immunol 2012; 23:688-689.
48. Senna G, Lombardi C, Canonica GW, et al. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol 2010; 126:668-669.
49. Scurati S, Frati F, Passalacqua G, et al. Adherence issues related to sub-lingual immunotherapy as perceived by allergists. Patient Prefer Adherence 2010; 4:141-145.
50. Passalacqua G, Frati F, Puccinelli P, et al. Adherence to sublingual immu-notherapy: the allergists' viewpoint. Allergy 2009; 64:1796-1797.